fusafungine fusafungine fusafungine (inn), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. it also possesses anti-inflammatory properties. fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating d-α-hydroxyvaleric acid and l-n-methylamino acid residues, produced by the ascomycete fusarium lateritium, and marketed by servier under the trade names locabiotal, bioparox, and locabiosol. fusafungineclinical dataother namesfusafunginahfs/drugs.cominternational drug namesatc coder02ab03 (who) identifiers iupac name cyclo cas number1393-87-9 ypubchem cid3084092drugbankdb08965 nunii65dd690w0ckeggd08002 ncomptox dashboard (epa)dtxsid50912008 echa infocard100.014.306 chemical and physical dataformulac33h57n3o9molar mass639.81 g·mol−13d model (jsmol)interactive imagemelting point125 to 129 °c (257 to 264 °f) smiles cc(c)1c(=o)oc(c(=o)n((c(=o)oc(c(=o)n((c(=o)oc(c(=o)n1c)c(c)c)c(c)c)c)c(c)c)c(c)c)c)c(c)c ny (what is this?) (verify) according to a pooled analysis study done in the uk for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from day 0 to day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo. in february 2016, the european medicines agency recommended the withdrawal of fusafungine from the market due to rare but severe allergic reactions (mainly bronchospasms).